olivLaw · European equity research
Orion Oyj ORNBV.HE
Finland · Nasdaq Helsinki · Vertical: Listed companies from Finland
Orion Oyj is a Finnish pharmaceutical group that develops and sells innovative medicines, generics, consumer health and animal health products, and also manufactures active pharmaceutical ingredients in-house. The company aims to strengthen its position in Europe and Asia Pacific, which makes it relevant to investors and the public.
At the close of 05 Nov 2026, Orion Oyj (ORNBV.HE) stock was 101.30 EUR (−0.20% on the day), with market capitalisation 14.2 bn EUR, P/E 28.5 on diluted EPS of 3.56 EUR over the last 12 months, dividend yield 1.62%, beta 0.42, 52-week range 56.85–101.50 EUR.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 81.0
- overbought (≥ 70)
- Bollinger (20, 2)
- 78.84 – 105.55
- in the upper half of the band · %B 0.84 · band width 29.0%
- SMA 50 / 200
- 85.48 / 75.20
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 4.83 / 4.07
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +24.5% | −0.6% | +25.2 pp | — |
| 3 months | +24.1% | −4.2% | +28.3 pp | — |
| 6 months | +45.7% | +4.3% | +41.3 pp | — |
| Year to date | +59.2% | +7.5% | +51.6 pp | — |
| 1 year | +74.5% | +9.9% | +64.6 pp | −1.2% |
| 3 years | +174.9% | +49.8% | +125.1 pp | +6.8% |
| 5 years | +166.1% | +42.8% | +123.3 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 100 percentile of its own 3-quarter history (min 17.9, median 18.2, max 25.5; quarters with earnings only).
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1.2 bn | 1.5 bn | 1.9 bn |
| Revenue YoY | unavailable | +29.6% | +22.5% |
| Net income | 216.8 m | 329.9 m | 500.3 m |
| Net income YoY | unavailable | +52.2% | +51.7% |
| Diluted EPS | 1.54 | 2.35 | 3.56 |
| Diluted EPS YoY | unavailable | +52.6% | +51.5% |
| net % | 18.2% | 21.4% | 26.5% |
| Free cash flow | 53.4 m | 231.1 m | 243.4 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 160.9 m EUR
- Financial debt
- 305.4 m EUR
- Net debt
- 144.5 m EUR
- Equity
- 1.3 bn EUR
- Total assets
- 2.0 bn EUR
- Debt / equity
- 0.24x
- Current ratio
- 2.40x
- ROE
- 43.7%
- ROA
- 27.5%
- FCF margin
- 12.9%
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 1.2 bn | 1.5 bn | 1.9 bn | esef· 04 Mar 2026verified |
| Cost of revenue | 531.9 m | 596.0 m | 676.5 m | esef· 04 Mar 2026verified |
| Gross profit | 657.7 m | 946.4 m | 1.2 bn | esef· 04 Mar 2026verified |
| Research & development | 126.9 m | 179.6 m | 210.4 m | esef· 04 Mar 2026verified |
| Operating income | 274.9 m | 416.6 m | 631.6 m | esef· 04 Mar 2026verified |
| Pre-tax income | 271.9 m | 413.1 m | 627.8 m | esef· 04 Mar 2026verified |
| Income tax | 55.1 m | 83.2 m | 127.5 m | esef· 04 Mar 2026verified |
| Net income | 216.8 m | 329.9 m | 500.3 m | esef· 04 Mar 2026verified |
| Diluted EPS | 1.54 | 2.35 | 3.56 | esef· 04 Mar 2026verified |
| Dividend per share | 1.60 | 1.62 | 1.64 | esef· 04 Mar 2026verified |
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 106.7 m | 205.6 m | 160.9 m | esef· 04 Mar 2026verified |
| Inventories | 362.2 m | 418.6 m | 456.3 m | esef· 04 Mar 2026verified |
| Current assets | 825.3 m | 1.0 bn | 1.3 bn | esef· 04 Mar 2026verified |
| Goodwill | 87.2 m | 87.2 m | 87.2 m | esef· 04 Mar 2026verified |
| Total assets | 1.4 bn | 1.6 bn | 2.0 bn | esef· 04 Mar 2026verified |
| Short-term debt | 29.0 m | 30.0 m | 190.1 m | esef· 04 Mar 2026verified |
| Long-term debt | 171.0 m | 297.2 m | 115.3 m | esef· 04 Mar 2026verified |
| Current liabilities | 264.8 m | 273.4 m | 560.3 m | esef· 04 Mar 2026verified |
| Total liabilities | 548.6 m | 624.1 m | 725.3 m | esef· 04 Mar 2026verified |
| Equity | 890.1 m | 1.0 bn | 1.3 bn | esef· 04 Mar 2026verified |
| Shares outstanding at year end | 140.8 m | 140.4 m | 140.5 m | esef· 04 Mar 2026derived |
Cash flow · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 119.0 m | 293.4 m | 316.8 m | esef· 04 Mar 2026verified |
| Capex | 65.6 m | 62.3 m | 73.4 m | esef· 04 Mar 2026verified |
| Free cash flow | 53.4 m ≈ | 231.1 m ≈ | 243.4 m ≈ | esef· 04 Mar 2026derived |
| Investing cash flow | -108.4 m | -85.2 m | -98.6 m | esef· 04 Mar 2026verified |
| Financing cash flow | -243.2 m | -108.8 m | -263.6 m | esef· 04 Mar 2026verified |
| Dividends paid | 224.9 m | 228.0 m | 231.1 m | esef· 04 Mar 2026verified |
| Share repurchases | 0 | 0 | — | esef· 11 Mar 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 56.2% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 14.2 bn EUR
Key indicators
Coverage and freshness
Score by group
56% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 22.30 – 65.86 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E29.31 – 65.86 (Mid 39.51)23 companies used · median multiple 11.1x · quartiles 8.2x – 18.5xALMA.HE, APETIT.HE, ASPO.HE, ATRAV.HE, BIOBV.HE, CAPMAN.HE, CONSTI.HE, DIGIA.HE, ELEAV.HE, ELISA.HE, ENENTO.HE, ETTE.HE, FORTUM.HE, FSECURE.HE, GLA1V.HE, GRK.HE, HARVIA.HE, ICP1V.HE, ILKKA.HE, INVEST.HE, KALMAR.HE, KAMUX.HE, KCR.HE
- Dividend discount (DDM)22.30 – 30.41 (Mid 25.74)
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 56.2% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 39.4% | 100 (vs peers) | 19% |
| Net margin · Quality | 26.5% | 95 (vs peers) | 11% |
| FCF conversion · Quality | 48.7% | 27 (on a fixed band) | 11% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.4x | 100 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | 28.5x | 25 (vs peers) | 19% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 1.7% | 21 (on a fixed band) | 15% |
| Shareholder yield (distributions) · Returns | 1.6% | 23 (on a fixed band) | 11% |
| Payout ratio (FCF) · Returns | 94.9% | 36 (on a fixed band) | 7% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality79/100 · 3/3 factors with a value
- Returns28/100 · 2/2 factors with a value
- Valuation23/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Orion Oyj (ORNBV.HE). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 1.9 bn EUR in 2025; YoY growth 22.5%; net margin 26.5%; ROE 43.7%.
The estimated value range is 25.81–48.14 EUR per share (median of 2 methods, agreement: high); assumptions are illustrative. Against the central value of 32.62 EUR, the price of 101.30 EUR leaves a potential of -67.8% (value / price − 1) and a margin of safety of -210.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 56.2% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 39.4%
- Net margin: 26.5%
- Current ratio: 2.4x
What contradicts it
- FCF conversion: 48.7%
- P/E (TTM): 28.5x
- FCF yield: 1.7%
- Shareholder yield (distributions): 1.6%
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, EV/EBITDA.
Versus the vertical median
Listed companies from Finland · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| FORTUM.HEFortum Oyj | 20.8 bn | 27.2 | 8.7% | 15.3% | −14.0% | +32% / +81% |
| ORNBV.HEOrion Oyj | 14.2 bn | 28.5 | 43.7% | 26.5% | +22.5% | +64% / +178% |
| ELISA.HEElisa Oyj | 5.6 bn | 16.3 | 27.0% | 15.2% | +3.0% | −8% / −15% |
| KALMAR.HEKalmar Oyj | 2.4 bn | 14.7 | 24.1% | 9.4% | +1.2% | +0% / unavailable |
| KCR.HEKonecranes Oyj | 2.2 bn | 5.6 | 20.3% | 9.5% | −0.9% | −4% / +134% |
| EXEL.HEExel Composites Oyj | 1.8 bn | — | -18.5% | -5.3% | +3.6% | +163% / +74% |
| BITTI.HEBittium Oyj | 1.2 bn | 55.8 | 17.5% | 17.9% | +40.1% | +73% / +603% |
| ALMA.HEAlma Media Oyj | 1.2 bn | 21.2 | 23.0% | 16.9% | +4.6% | +9% / +57% |
| FIA1S.HEFinnair Oyj | 927.4 m | 50.4 | 2.9% | 0.6% | +1.9% | +54% / +22% |
| GRK.HEGRK Infra Oyj | 788.5 m | 18.3 | 27.8% | 4.9% | +19.7% | +52% / unavailable |
| HARVIA.HEHarvia Oyj | 768.7 m | 29.3 | 21.0% | 13.3% | +13.5% | −1% / +64% |
| ATRAV.HEAtria Oyj | 451.7 m | 11.1 | 9.8% | 2.2% | +3.3% | +13% / +57% |
| ANORA.HEAnora Group Oyj | 317.6 m | 57.8 | 1.4% | 0.8% | −4.9% | +26% / +11% |
| CAPMAN.HECapMan Oyj | 300.2 m | 23.1 | 6.8% | 20.9% | +9.4% | −8% / −20% |
| ICP1V.HEIncap Oyj | 261.0 m | 18.7 | 10.4% | 6.5% | −6.7% | −3% / +37% |
| FSECURE.HEF-Secure Oyj | 243.7 m | 10.9 | 43.4% | 15.3% | −0.4% | −17% / −23% |
| ASPO.HEAspo Oyj | 219.4 m | 9.3 | 15.4% | 5.0% | +2.1% | +2% / +9% |
| ETTE.HEEtteplan Oyj | 173.7 m | 16.4 | 8.8% | 2.9% | +0.1% | −27% / −51% |
| DIGIA.HEDigia Oyj | 131.6 m | 10.5 | 14.5% | 5.9% | +5.5% | −16% / −12% |
| ILKKA.HEIlkka Oyj | 93.8 m | 8.1 | 6.2% | 30.8% | +22.6% | +0% / +21% |
| CONSTI.HEConsti Oyj | 77.4 m | 11.6 | 15.3% | 2.0% | +2.9% | −8% / −6% |
| APETIT.HEApetit Oyj | 75.6 m | 8.4 | 8.2% | 5.4% | +3.1% | −14% / −3% |
| ESENSE.HEEnersense International Oyj | 74.9 m | 74.7 | 3.1% | 0.4% | −27.7% | +12% / +9% |
| CTH1V.HEComponenta Oyj | 66.1 m | 324.0 | 0.8% | 0.2% | −4.6% | +49% / +182% |
| KAMUX.HEKamux Oyj | 47.4 m | 10.3 | 4.2% | 0.5% | +0.8% | −40% / −77% |
1- and 3-year price returns: for ORNBV.HE from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (EUR)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 66.20 Total return -33% · Per year -33% | 116.49 Total return 17% · Per year 17% | 174.74 Total return 75% · Per year 75% |
| 3 years | 78.52 Total return -18% · Per year -6% | 154.06 Total return 59% · Per year 17% | 251.63 Total return 157% · Per year 37% |
| 5 years | 93.14 Total return 0% · Per year 0% | 203.75 Total return 114% · Per year 16% | 362.35 Total return 274% · Per year 30% |
- Exit P/E± 38.52
- Net margin± 26.96
- Annual revenue growth± 20.11
- Annual dilution± 2.27
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Orion Oyj is a Finnish pharmaceutical group that develops and sells innovative medicines, generics, consumer health and animal health products, and also manufactures active pharmaceutical ingredients in-house. The company aims to strengthen its position in Europe and Asia Pacific, which makes it relevant to investors and the public 1.
SWOT
Strengths
- A diversified portfolio across several divisions, from innovative medicines to generics and animal health.
- In-house active ingredient manufacturing through Fermion, which supports all divisions.
- Research and development expertise in oncology and pain management.
Weaknesses
- Dependence on a complex value chain and on suppliers exposed to environmental and supply risks.
- Active ingredient production generates hazardous waste in significant quantities.
- Some products depend on reagents obtained from vulnerable species, creating exposure in quality control.
Opportunities
- Expansion in Asia Pacific and Japan could open new revenue sources.
- Establishing operations in the United States could strengthen research and commercialisation capabilities.
- Demand growth in oncology and pain management could support the innovative divisions.
Threats
- Stricter environmental regulation could raise compliance costs and required investment.
- Water and energy restrictions could increase the costs of intensive production.
- Additional environmental assessments could make some new products unprofitable.
Risks
- Rules on pharmaceutical residuesmedium
Extended producer responsibility requirements for medicines could generate additional costs, and these requirements could be extended over time.
- Dependence on LAL reagenthigh
A disruption in access to reagents derived from horseshoe crabs could affect critical quality control processes, although synthetic alternatives exist.
- Pollution incident riskhigh
A significant pollution incident in own operations could damage reputation and would require repair investment.
- Climate pressure on pricingmedium
If emission mitigation measures are not considered adequate, the company could lose access to some tenders or be forced to reduce prices.
- Dependence on water and energymedium
Rising energy prices and water scarcity could increase the costs of energy-intensive processes across the value chain.
Investment thesis
What would need to be true (bull case)
- If the growth strategy in Europe, Asia Pacific and the United States is delivered, diversification across divisions could support long-term value creation.
- In-house active ingredient manufacturing through Fermion could offer cost and quality control advantages.
- Expertise in oncology and pain management could generate high-value products.
What would break the thesis
- If environmental regulation tightens quickly, compliance costs could reduce profit margins.
- Dependence on a complex value chain could expose the company to supply interruptions.
- International expansion requires significant investment, and results could take longer to materialise.
What to watch
- Progress of the expansion strategy in Asia Pacific and the United States2027
- Developments in regulation on pharmaceutical residues2027
- Availability of the LAL reagent and of synthetic alternativesnext 10-K
- Results of the strategy assessment and sustainability indicatorsnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
According to the annual report for the year ended 31 December 2025, the group strategy rests on a customer-driven portfolio, geographic expansion and growth enablers such as safety, sustainability and global commercialisation capabilities 1. The strategy is confirmed annually by the board of directors and reviewed quarterly in sessions with the Executive Team 1. The company aims to strengthen its position in Europe and expand operations in Asia Pacific including Japan, and to establish operations in the United States for research and commercialisation 1. Orion describes building an end-to-end value chain, from molecule development to marketing and distribution, as a central element of its strategy 1.
The portfolio includes divisions with distinct roles: Innovative Medicines, focused on oncology and pain management, is described as the global growth driver; Branded Products aims to be an impactful player in respiratory, central nervous system and women's health in Europe and Asia 1. Generics and Consumer Health provides a stable base through its generics and consumer health products, and Animal Health focuses on companion and livestock animals 1. Fermion manufactures key active ingredients for all divisions 1.
Orion states its commitment to patient safety and sustainability across the entire product life cycle, which it also presents as a point of differentiation with European partners 1. In 2025 the company amended its operating environment scenarios with a heightened focus on climate change and biodiversity to keep its strategy resilient 1.
Segments
Innovative Medicines
The Innovative Medicines division focuses on oncology and pain management, leveraging Orion's research and development expertise in these fields, which it considers crucial and expanding 1. Management describes it as the global growth driver of the group 1.
Generics and Consumer Health
This division offers a large cost-effective generics portfolio for European hospitals and other selected markets, complemented by value-added complex generics and consumer health products 1. It is described as the solid bedrock of the group, with a focus on affordable quality medicines 1.
Branded Products
The Branded Products division continues to build on its strength in respiratory and Parkinson's disease, with the target of becoming an impactful player in respiratory, central nervous system and women's health in Europe and Asia 1.
Market context
Orion operates in the pharmaceutical industry, where the European market is an important part of its business, and expansion into Asia Pacific and the United States is part of its growth strategy 1. The company notes that the global nature of its business makes it necessary to monitor geopolitical developments and different markets 1.
The pharmaceutical industry increasingly depends on environmental and sustainability regulation, and Orion assesses how these affect costs and market access, including environmental risk assessment requirements for new products 1.
Trends
- Stricter environmental regulationheadwind
The European initiative to limit pharmaceuticals in the environment could generate additional costs for Orion through extended producer responsibility allocations, if these rules apply 1.
- Sustainability reporting requirementsmixed
Sustainability reporting and due diligence requirements can raise compliance costs, but can also strengthen trust among partners and authorities 1.
- Expansion in Asia Pacifictailwind
If the expansion of operations in Asia Pacific and Japan succeeds, it could open new growth sources for the Branded Products and Innovative Medicines divisions 1.
- Environmental pressure on productionheadwind
Water stress, climate change and resource restrictions could raise energy and water costs for energy-intensive production 1.
Competitive position
Orion competes in European and global pharmaceutical markets with other companies developing innovative medicines, generics, consumer health and animal health products. The sources provided do not describe competitors in detail, so the list below is limited to what is mentioned in the company's documents.
Orion's competitive position rests on research and development capability in oncology and pain, an integrated value chain and in-house active ingredient manufacturing through Fermion 1. The company aims to build global commercialisation capabilities to compete at a larger scale 1.
- Other European innovative and generic medicines producers
European companies active in the same therapeutic segments, mentioned only generically in the source without named identification.
- Generics producers supplying European hospitals
Competitors in the generics segment offering cost-effective portfolios, the same segment where Orion describes its solid base.
- Animal health companies
Competitors in the animal health division for companion and livestock animals, not named in the source.
- Companies active in oncology and pain management
Competitors in the therapeutic areas Orion considers priorities for global growth.
News & filings
In the press
- ORION a obținut autorizația de construire pentru o nouă platformă industrială la Ciulnița. Prima etapă prevede peste 4.400 mp de construcțiiFinancial Intelligence (RO) · 27 Oct 2026 · RO
- Stellar collision may explain why Orion Nebula's planet-forming disks appear younger than its starsPhys.org · 23 Oct 2026 · EN
- Orion expands Custard cream cake production in Korea, Vietnam, India as global demand surgesKorea Times — Business · 22 Oct 2026 · EN
- Kagi Ends Orion Browser Development for Linux, Will Open-Source ItHacker News · 05 Oct 2026 · EN
- Development has ended on Orion for LinuxOMG! Ubuntu · 03 Oct 2026 · EN
- An Update on Orion for Linux and WindowsHacker News · 03 Oct 2026 · EN
- Orion Energy (OESX) Raises Guidance. How Firm is the Retailer Opportunity?Yahoo Finance — News · 20 Sept 2026 · EN
- Ukraine Says It Hit Russian Orion Drone Control Station in CrimeaKyiv Post · 18 Sept 2026 · EN
- Ukrainian forces strike control station for Russian Orion drones in CrimeaUkrainska Pravda (UA, EN) · 18 Sept 2026 · EN
- Orion for Linux beta update now lets you customise the toolbarOMG! Ubuntu · 15 Sept 2026 · EN
- Orion Adds BlackRock, Fidelity, Vanguard to its Tailored Allocation PortfoliosYahoo Finance — News · 01 Sept 2026 · EN
- Un „fluviu” de gaz cosmic a determinat planetele din constelația Orion să intre pe orbite înclinateG4Media · 17 Aug 2026 · RO
- Ukraine's General Staff: defence forces strike attack UAV storage site and Orion control station in CrimeaUkrainska Pravda (UA, EN) · 17 Aug 2026 · EN
- Orion Browser by KagiHacker News · 19 Jul 2026 · EN
- Astronauții misiunii Artemis II s-au reîntâlnit cu capsula Orion după zborul istoric în jurul Lunii. Ce urmează pentru programul NASAMediafax · 09 Jul 2026 · RO
- Artemis II astronauts reunite with Orion after record-breaking Moon missionEuronews Next · 09 Jul 2026 · RO
- Over 60 targets hit overnight: Ukrainian forces strike Russian air defences and rare Orion UAVs in Crimea – videoUkrainska Pravda (UA, EN) · 23 Jun 2026 · RO
Annual reports (ESEF)
- Annual report 202504 Mar 2026
- Annual report 202411 Mar 2025
- Annual report 202311 Mar 2025
Sources
- [1] Annual report, fiscal year ended 2025-12-31 (ESEF) · SEC / Orion Oyj · 31 Dec 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.